Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival
time of 10-12 months. Clinically, these poor outcomes are attributed to several factors …

Apoptosis is the programmed cell death which maintains the healthy survival/death balance
in metazoan cells. Defect in apoptosis can cause cancer or autoimmunity, while enhanced …

Cancer-associated fibroblasts (CAFs) comprise the majority of the tumor bulk of pancreatic
ductal adenocarcinomas (PDACs). Current efforts to eradicate these tumors focus …

Gemcitabine is the first-line treatment for pancreatic adenocarcinoma, but is increasingly
used to treat breast, bladder, and non-small cell lung cancers. Despite such broad use …

Resistance to chemotherapy limits the effectiveness of anti‐cancer drug treatment. Tumours
may be intrinsically drug‐resistant or develop resistance to chemotherapy during treatment …

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the
United States with a median survival of< 6 mo and a dismal 5-yr survival rate of 3%–5%. The …

Activation of transcription factor NF-κB is frequently encountered in tumor cells and
contributes to aggressive tumor growth and resistance to chemotherapy and ionizing …

The cytotoxicity of chemotherapeutic agents is attributed to apoptosis. Acquired resistance to
the effects of chemotherapy has emerged as a significant impediment to effective cancer …

Gemcitabine is currently the best treatment available for pancreatic cancer, but the disease
develops resistance to the drug over time. Agents that can either enhance the effects of …

Background Both hereditary and sporadic forms of chronic pancreatitis are associated with
an increased risk of developing pancreatic ductal adenocarcinoma (PDA). Inflammation has …